Future microbiology最新文献

Interplay of gut microbiota in Kawasaki disease: role of gut microbiota and potential treatment strategies.

IF 2.5 4区生物学

Future microbiology Pub Date : 2025-02-27 DOI: 10.1080/17460913.2025.2469432

Qing Yang, Yaqing Kang, Wei Tang, Meng Li, Cuifen Zhao

{"title":"Interplay of gut microbiota in Kawasaki disease: role of gut microbiota and potential treatment strategies.","authors":"Qing Yang, Yaqing Kang, Wei Tang, Meng Li, Cuifen Zhao","doi":"10.1080/17460913.2025.2469432","DOIUrl":"https://doi.org/10.1080/17460913.2025.2469432","url":null,"abstract":"Kawasaki disease (KD) is an acute systemic immune vasculitis with predominant involvement of the medium and small arteries. It mostly affects pediatric patients, representing the most common form of pediatric vasculitis in children less than 5 years old. Numerous diseases, especially those related to the immune system, have established links with the intestinal flora. Recent studies have investigated the intestinal flora changes throughout the management of KD. There was gut microbiota dysbiosis in pediatric KD at the acute phase, particularly the downregulation of short-chain fat acids-producing microbiota and the over-proliferation of opportunistic pathogens. The relationship between the response to therapies in individuals with KD and specific microbiota remains uncertain. Targeted microbial supplements and dietary regulation may serve as potential measures to alleviate KD complications and thus improve prognosis. This review provides an overview of the current understanding of the interplay of the gut microbiota and KD. Furthermore, it discusses the possibility of altering the gut microbiota to reinstate a healthy condition.","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"1-13"},"PeriodicalIF":2.5,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cefepime-enmetazobactam: first approved cefepime-β- lactamase inhibitor combination for multi-drug resistant Enterobacterales.

IF 2.5 4区生物学

Future microbiology Pub Date : 2025-02-26 DOI: 10.1080/17460913.2025.2468112

Tanaya Bhowmick, Rafael Canton, Federico Pea, Juan Quevedo, Anne Santerre Henriksen, Jean-François Timsit, Keith S Kaye

{"title":"Cefepime-enmetazobactam: first approved cefepime-β- lactamase inhibitor combination for multi-drug resistant Enterobacterales.","authors":"Tanaya Bhowmick, Rafael Canton, Federico Pea, Juan Quevedo, Anne Santerre Henriksen, Jean-François Timsit, Keith S Kaye","doi":"10.1080/17460913.2025.2468112","DOIUrl":"10.1080/17460913.2025.2468112","url":null,"abstract":"Cefepime-enmetazobactam is a β-lactam/β-lactamase inhibitor (BL/BLI) combination that has demonstrated potent activity against extended spectrum beta-lactamase (ESBL)-producing Enterobacterales, recently approved by the US FDA for the treatment of complicated urinary tract infections (cUTI) and by the European Medicines Agency and the UK Healthcare products Regulatory Agency for the treatment of cUTI, hospital-acquired pneumonia including ventilator-associated pneumonia and bacteremia in adults. Cefepime is a 4th generation cephalosporin with a broad spectrum bactericidal activity and enhanced stability to degradation by chromosomal and plasmid-mediated AmpC cephalosporinases as well as carbapenemase OXA-48 like enzymes. Enmetazobactam is a novel penicillanic acid sulfone β-lactamase inhibitor structurally similar to tazobactam with activity against CTX-M, TEM, and SHV ESBL, and other class A β-lactamases, that restores cefepime activity in vitro and in vivo against ESBLs-producing Enterobacterales. The targeted activity of cefepime-enmetazobactam against ESBLs infections which are resistant to common antibiotics, together with its superior results against piperacillin/tazobactam in a phase 3 trial make this new BL/BLI combination an effective carbapenem sparing option for the treatment of serious infections caused by ESBLs-producing Enterobacterales. In addition, if clinical data are supportive, cefepime-enmetazobactam has a potential role in the treatment of pathogens co-producing OXA-48 like enzymes along with ESBLs.","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"1-10"},"PeriodicalIF":2.5,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143500624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plain language summary: efficacy and safety of gepotidacin, a new oral antibiotic, compared with nitrofurantoin, a commonly used oral antibiotic, for treating uncomplicated urinary tract infection.

IF 2.5 4区生物学

Future microbiology Pub Date : 2025-02-23 DOI: 10.1080/17460913.2025.2460387

Florian Wagenlehner, Caroline R Perry, Thomas M Hooton, Nicole E Scangarella-Oman, Helen Millns, Salim Janmohamed, Melissa Kramer, Pamela Kushner, Marcy Powell, Emily Jarvis, Jeremy Dennison, Amanda Sheets, Deborah Butler, John Breton

引用次数: 0

Efficacy of nitrofuran derivatives against biofilms of Histoplasma capsulatum strains and their in vivo toxicity.

IF 2.5 4区生物学

Future microbiology Pub Date : 2025-02-05 DOI: 10.1080/17460913.2025.2457286

Carolina Orlando Vaso, Níura Madalena Bila, Rosângela Aparecida Moraes da Silva, Angélica Romão de Carvalho, Jennyfie Araújo Belizário, Fabiana Pandolfi, Daniela De Vita, Martina Bortolami, Maria José Soares Mendes-Giannini, Luigi Scipione, Roberto Di Santo, Roberta Costi, Caroline Barcelos Costa-Orlandi, Ana Marisa Fusco-Almeida

{"title":"Efficacy of nitrofuran derivatives against biofilms of Histoplasma capsulatum strains and their in vivo toxicity.","authors":"Carolina Orlando Vaso, Níura Madalena Bila, Rosângela Aparecida Moraes da Silva, Angélica Romão de Carvalho, Jennyfie Araújo Belizário, Fabiana Pandolfi, Daniela De Vita, Martina Bortolami, Maria José Soares Mendes-Giannini, Luigi Scipione, Roberto Di Santo, Roberta Costi, Caroline Barcelos Costa-Orlandi, Ana Marisa Fusco-Almeida","doi":"10.1080/17460913.2025.2457286","DOIUrl":"https://doi.org/10.1080/17460913.2025.2457286","url":null,"abstract":"Aim: To evaluate the efficacy of two nitrofuran derivatives against biofilms formed by two strains of Histoplasma capsulatum and to study the toxicity of these compounds in alternative models: Caenorhabditis elegans, Galleria mellonella, and zebrafish.Methods: The metabolic activity of biofilms was measured after treatment using the XTT reduction assay. Scanning electron microscopy (SEM) and confocal microscopy were used to observe damage to mature biofilms. Survival curves were generated for G. mellonella, while percentage survival was determined for C. elegans and zebrafish.Results: The compounds showed efficacy against early and mature biofilms at concentrations equal to or up to two times higher than those required to eliminate planktonic fungal cells (3.90 to 31.25 μg/mL). Micrographs showed a reduction in metabolic activity, biofilm thickness, and extracellular matrix. In addition, the compounds showed little or no toxicity in alternative models, even at the highest concentrations tested.Conclusion: These results are promising for the development of new therapeutic alternatives, especially for species, such as H. capsulatum, which are recognized as high-priority pathogens. Few studies have investigated resistance and antifungal treatment targeting biofilms of this species, making this work a relevant contribution to future approaches.","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"1-10"},"PeriodicalIF":2.5,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction.

IF 2.5 4区生物学

Future microbiology Pub Date : 2025-02-05 DOI: 10.1080/17460913.2025.2463265

引用次数: 0

A novel inhibitory strategy of Leishmania major using Kluyveromyces lactis and Saccharomyces cerevisiae killer toxins. 利用乳酸克鲁维酵母菌和酿酒酵母杀手毒素抑制大利什曼病菌的新策略。

IF 2.5 4区生物学

Future microbiology Pub Date : 2025-02-01 Epub Date: 2024-12-20 DOI: 10.1080/17460913.2024.2443329

Azadeh Zolfaghari, Keivan Beheshti-Maal, Ali Mohammad Ahadi, Ramesh Monajemi

{"title":"A novel inhibitory strategy of Leishmania major using Kluyveromyces lactis and Saccharomyces cerevisiae killer toxins.","authors":"Azadeh Zolfaghari, Keivan Beheshti-Maal, Ali Mohammad Ahadi, Ramesh Monajemi","doi":"10.1080/17460913.2024.2443329","DOIUrl":"10.1080/17460913.2024.2443329","url":null,"abstract":"Aim: Leishmaniasis is a globally prevalent parasitic disease that has drawn significant attention. Killer yeasts offer a novel biological control method, presenting a potential alternative for treating leishmaniasis. This study evaluates the antileishmanial activity of Kluyveromyces lactis and Saccharomyces cerevisiae killer toxins against Leishmania major.Materials & methods: Killer yeasts were isolated using the Well method. The genes encoding K2 and K.L killer toxins were identified by PCR, and the toxins were purified via SDS-PAGE. Antileishmanial and cytotoxic effects on L. major promastigotes and amastigotes were evaluated using the MTT assay.Results: The first killer isolate was identified as Saccharomyces cerevisiae ZBAM (GenBank accession: OQ376749.1) and the second as Kluyveromyces lactis ZBAM (GenBank accession: OQ401036.1). IC50 values of K2 and K.L toxins against L. major promastigotes were significantly lower than Glucantime and Amphotericin B. The EC50 values at 24 hours for Glucantime, K2, and K.L were 11.83 ± 0.02 μg/ml, 2.35 ± 0.01 μg/ml, and 3.23 ± 0.03 μg/ml, respectively. The EC50 values for K2 and K.L against L. major amastigotes were also lower than Glucantime.Conclusion: This is the first report of the antileishmanial effects of K2 and K.L toxins against L. major, suggesting these yeasts as promising candidates for biological leishmaniasis treatment.","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"189-199"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812320/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The dual role of microbes in food safety and human health: from pathogens to probiotics. 微生物在食品安全和人类健康中的双重作用：从病原体到益生菌。

IF 2.5 4区生物学

Future microbiology Pub Date : 2025-02-01 Epub Date: 2024-12-05 DOI: 10.1080/17460913.2024.2437273

Helen Onyeaka, Olumide Odeyemi

引用次数: 0

Sex and gender in rhinosinusitis: a review. 鼻鼻窦炎的性别和性别：综述。

IF 2.5 4区生物学

Future microbiology Pub Date : 2025-02-01 Epub Date: 2024-12-14 DOI: 10.1080/17460913.2024.2441010

C S Thornton, L Radu, N Boechler, J Clark, R Somayaji

引用次数: 0

Evaluation of the antibacterial properties of four bioactive biomaterials for chronic wound management. 四种生物活性材料在慢性伤口治疗中的抗菌性能评价。

IF 2.5 4区生物学

Future microbiology Pub Date : 2025-02-01 Epub Date: 2025-01-15 DOI: 10.1080/17460913.2025.2453334

Sarah Fakher, David Westenberg

{"title":"Evaluation of the antibacterial properties of four bioactive biomaterials for chronic wound management.","authors":"Sarah Fakher, David Westenberg","doi":"10.1080/17460913.2025.2453334","DOIUrl":"10.1080/17460913.2025.2453334","url":null,"abstract":"Aim: Chronic wound infections present a prevalent medical issue and a multifaceted problem that significantly impacts healthcare systems worldwide. Biofilms formed by pathogenic bacteria are fundamental virulence factors implicated in the complexity and persistence of bacterial-associated wound infections, leading to prolonged recovery times and increased risk of infection. This study aims to investigate the antibacterial effectiveness of commonly employed bioactive wound healing compositions with a particular emphasis on their effectiveness against common bacterial pathogens encountered in chronic wounds - Staphylococcus epidermidis, Escherichia coli, and Pseudomonas aeruginosa to identify optimal wound product composition for managing chronic wound infections.Methods: This study tested the antibacterial and antibiofilm effectiveness of four bioactive wound healing materials by performing in vitro antibacterial assays and measuring ion release profiles.Results: The anti-biofilm effectiveness differed extensively among the biomaterials tested and slightly among the bacterial species. Particularly, copper and zinc-doped borate bioactive glass wound healing compositions inhibited the three clinically relevant bacteria in both planktonic and biofilm forms, which were found to be ascribed to the copper and zinc gradual release.Conclusion: The findings suggest that copper and zinc-doped bioactive glasses hold great promise for improving chronic wound management by providing strong antibacterial action and promoting faster healing.","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"247-258"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A rare case of granulomatous mastitis by Brucella species. 一例罕见的布鲁氏菌引起的肉芽肿性乳腺炎。

IF 2.5 4区生物学

Future microbiology Pub Date : 2025-02-01 Epub Date: 2024-11-16 DOI: 10.1080/17460913.2024.2429263

Necati Mumcu, Yusuf Emre Ozdemir

引用次数: 0